Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 3/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5428269 | 0.94 | HDAC6 (0.56) | CES2CES1HDAC6HDAC2HDAC8 | |
| SCHEMBL15948139 | 0.89 | TRPV1 (0.76) | HDAC6HDAC8TRPV1NPC1RAB9A | |
| SCHEMBL21628855 | 0.89 | HPGD (0.76) | CES2CES1HDAC6HDAC2HDAC8 | |
| SCHEMBL21120792 | 0.85 | HDAC6 (0.57) | CES2CES1HDAC6HDAC2HDAC8 | |
| SCHEMBL26163219 | 0.83 | CES2 (0.57) | CES2CES1TRPV1NPC1CRHBP | |
| SCHEMBL250247 | 0.83 | HDAC6 (0.80) | HDAC6HDAC2HDAC8HPGDTSHR | |
| SCHEMBL1004777 | 0.81 | CES2 (0.59) | CES2HDAC6HDAC8HTTSMN1; SMN2 | |
| SCHEMBL13247113 | 0.81 | HDAC2 (0.57) | HDAC6HDAC2HDAC8HPGDTSHR | |
| SCHEMBL6991977 | 0.81 | CES2 (0.59) | CES2CES1TRPV1NPC1CRHBP | |
| SCHEMBL21727750 | 0.80 | HDAC6 (0.52) | HDAC6HDAC2HDAC8HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | claimed |
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | claimed |
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | disclosed |
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2023-03-07 | — | — | US | disclosed |
| CN-115551864-A | Substituted tricyclic amides, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| CN-1041268-C | Method of controlling insects and acarids | FMC CORP (US) | 1998-12-23 | — | — | CN | disclosed |
| CN-1029123-C | Process for preparation of insecticidal cyclopropyl-substituted di(aryl) compounds | FMC CORP (US) | 1995-06-28 | — | — | CN | disclosed |
| CN-1020091-C | Cyclopropyl-substituted di (aryl) insecticidal compositions | FMC CORP (US) | 1993-03-17 | — | — | CN | disclosed |
| CN-1069962-A | The preparation method of parasiticidal cyclopropyl-replacement two (aromatic base) compound | FMC CORP (US) | 1993-03-17 | — | — | CN | disclosed |
| CN-1069168-A | Method for controlling insects and acarids | FMC CORP (US) | 1993-02-24 | — | — | CN | disclosed |
| WO-1993001715-A1 | 1,4-DIARYL-1-CYCLOPROPYL-4-SUBSTITUTED BUTANES AS INSECTICIDES AND ACARICIDES | FMC CORPORATION (US) | 1993-02-04 | — | — | WO | disclosed |
| CN-88101892-A | insecticidal cyclopropyl-substituted di (aryl) compounds | — | 1988-11-02 | — | — | CN | disclosed |
| US-3972931-A | N,N'-Disubstituted benzamidines | THE DOW CHEMICAL COMPANY (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | CES2 4691/4885CES1 4251/4885HDAC6 2492/4885 |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC1 | CES2 3332/4885CES1 615/4885HDAC6 313/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | CES2 4691/4885CES1 4251/4885HDAC6 2492/4885 |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC1 | CES2 3332/4885CES1 615/4885HDAC6 313/4885 |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC3 | CES2 3270/4885CES1 621/4885HDAC6 375/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | CES2 4573/4885CES1 2298/4885HDAC6 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.